Specialists from the UK Medicines and Healthcare products Regulatory Agency (MHRA) have published the results of a study that could significantly change the approach to preventing infections caused by Group A Streptococcus (Strep A). This bacterium is capable of triggering a wide spectrum of diseases — from mild throat and skin infections to severe complications, including scarlet fever and invasive forms of infection. Scientists have developed an innovative vaccination method that does not involve the use of injections. Such an approach potentially simplifies the immunization process, reduces needle anxiety in patients, especially children, and can facilitate the logistics of mass vaccination by eliminating the need for sterile needles and syringes. According to the researchers, the data obtained brings the creation of a full-fledged vaccine against Strep A closer to reality, work on which has been underway by the scientific community for a long time. Despite the prevalence of the infection and periodic outbreaks, an effective and widely available vaccine against this bacterium did not previously exist. Experts note that successful completion of further development stages could have significant implications for public health, particularly given Group A Streptococcus's ability to cause serious and in some cases fatal complications. For now, the research is at an early stage, and additional clinical trials will be required to confirm the efficacy and safety of the new vaccine.